Should Cerus prioritize expanding INTERCEPT Blood System compatibility with more blood collection platforms or focus on enhancing its performance with existing platforms?

Introduction

The trade-off we're examining today is whether Cerus should prioritize expanding INTERCEPT Blood System compatibility with more blood collection platforms or focus on enhancing its performance with existing platforms. This decision is crucial for Cerus' product strategy and market position in the blood safety industry. I'll analyze this trade-off by considering market expansion versus product improvement, evaluating the impacts on various stakeholders, and proposing a data-driven approach to make an informed decision.

Step 1

Clarifying Questions (3 minutes)

• Based on the current market share, I'm thinking INTERCEPT might already be compatible with major blood collection platforms. Could you give me an overview of our current platform compatibility and market penetration?

Why it matters: Helps assess the potential impact of expansion vs. improvement Expected answer: Compatible with 3-4 major platforms, 60% market penetration Impact on approach: Low compatibility would favor expansion, high would favor improvement

• Considering our revenue model, I assume we generate income from both system sales and per-use consumables. What's the current split between these revenue streams?

Why it matters: Influences whether to focus on new customer acquisition or increasing usage Expected answer: 30% system sales, 70% consumables Impact on approach: Higher consumables revenue might favor improving existing platforms

• Looking at user segments, I'm curious about the adoption rates among different types of blood centers. Are there significant differences between large hospitals, regional centers, and smaller clinics?

Why it matters: Identifies potential growth areas and user needs Expected answer: Higher adoption in large centers, lower in smaller clinics Impact on approach: Low adoption in smaller clinics might favor platform expansion

• Regarding technical feasibility, what's our current capacity for simultaneous development of new platform compatibility and performance improvements?

Why it matters: Determines if we can pursue both strategies or must choose Expected answer: Limited resources, can fully commit to one or partially to both Impact on approach: Resource constraints would necessitate a more focused strategy

• Considering timeline pressures, are there any upcoming regulatory changes or competitor moves that might influence our decision?

Why it matters: Identifies external factors that could impact prioritization Expected answer: New regulations expected in 18 months, competitor launching new product in 12 months Impact on approach: Imminent changes might favor quicker-to-market improvements